AMRX•benzinga•
Amneal Pharmaceuticals Expects To Meet Its 2024 Net Revenue, Adjusted EBITDA, And Adjusted EPS Guidance, Exceed Its Operating Cash Flow Guidance - Filing
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga